NCT03410979View on ClinicalTrials.gov

A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2737 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

November 25, 2016

Primary Completion Date

August 15, 2017

Study Completion Date

August 15, 2017

Conditions
Healthy
Interventions
DRUG

GLPG2737 single dose

GLPG2737 oral suspension, single ascending doses

DRUG

Placebo single dose

Placebo, oral suspension.

DRUG

GLPG2737 multiple dose

GLPG2737 oral suspension, multiple ascending doses, daily for 14 days.

DRUG

GLPG2737 multiple dose

Placebo, oral suspension, daily for 14 days

Trial Locations (1)

Unknown

PRA-EDS, Groningen

Sponsors

Lead Sponsor

Galapagos NV
All Listed Sponsors
lead

Galapagos NV

INDUSTRY

NCT03410979 - A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2737 in Healthy Subjects | Biotech Hunter | Biotech Hunter